Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Amar wil bijna 200 miljoen nieuwe aandelen uitgeven
Volgen
EXPLANATORY NOTES TO THE AGENDA OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS (EGM) OF ESPERITE N.V. to be held on 26 March 2020 at 14:00 hours CET at Immeuble le Patio, 35-37 Rue Louis Guérin, 69100 Villeurbanne, France Introduction These explanatory notes should be read in conjunction with the agenda for the EGM of Esperite N.V (Esperite, the Company) to be held on 26 March 2020. The paragraph numbering below corresponds with the numbering of the agenda items. 1. Opening and announcements 2. Business update Esperite has experience turbulent headwind during the last months. Esperite wants to update the shareholders and provide the relevant information about the recent developments. During the Q4 2018, Esperite, sole shareholder of CryoSave, took the decision to sell its stem cell activities. A process was put in place and some potential buyers were contacted. One of the main goals was to safeguard the integrity of ALL the samples processed and stored by CryoSave of the 18 years of activity. CryoSave has successfully put in place several measures in order to maintain the continuity of the commitment with the clients, guarantee the storage for ALL the samples. Despite the transparent communication deployed by CryoSave, some misunderstandings deserve an extended clarification. The management of the Group is of the opinion that Esperite should not account any liabilities from this operation. A detailed presentation is accessible on Esperite website:www.esperite.com/?page_id=7103 Esperite wants to take the opportunity to present a financial market update and an interim non audited 2018 financial report. 3. Esperite 2.0 Esperite has already announced its intention to take distance from the operative part of its activities and focus its effort on turning itself into an investment company with a focus on 2 Health Care and High-Tech Services. The group will present its strategy for the next years. 4. Change of Headquarters location Esperite NV is registered in Piet Heinstraat 11, 7204 JN Zutphen, Netherlands with a business address in Herengracht 282, 1016 BX Amsterdam Netherlands. The Board of Directors has decided to move the Headquarters and the Business Address to France, Immeuble le Patio, 35-37 Rue Louis Guérin, 69100 Villeurbanne France. Since 7 January 2020: The Company’s visiting and business address is now established in France; The actual headquarter operations, board meetings and General meetings are at the address of the new headquarters The company will conduct the necessary process to recruit and appoint a minimum of two French board members. The daily operations and administrative tasks are conducted by local team of employees which carry out their work in the headquarter address; The Company will conduct the necessary actions in order to be regulated by the French regulator; 5. Annual report 2018 – including Corporate Governance Consideration of the annual report by the Board of Directors for the 2018 financial year. In accordance with the principles of the Dutch Corporate Governance Code, the Company's approach to the implementation of the Dutch Corporate Governance Code as set out in the annual report is tabled for discussion at the AGM. The company has not been able to finalise its annual report for the year 2018 on due course. The company
5. Annual report 2018 – including Corporate Governance Consideration of the annual report by the Board of Directors for the 2018 financial year. In accordance with the principles of the Dutch Corporate Governance Code, the Company's approach to the implementation of the Dutch Corporate Governance Code as set out in the annual report is tabled for discussion at the AGM. The company has not been able to finalise its annual report for the year 2018 on due course. The company proposes to present an unaudited annual for 2018 to its shareholders. The Company is taking all the possible measure to remedy. The unaudited annual report 2018 will be available for download from the Company’s website (www.esperite.com) 3 weeks before the EGM. The company will present to the shareholders a market update for 2019 as well as half years figure for 2019. 6. Proposal to amend article 4 of the Company’s Articles of Association - Change of shares capital nominal value (Voting Item) During the last AGM, on 8 January 2019, the shareholders have approved to increase the value of share capital to 17’500’000,00 euro, composed of 175’000’000 shares of ten eurocent (EUR 0.10). The company’s Board of Directors proposes to reduce the shares nominal value from ten eurocent (EUR 0.10) to one eurocent (EUR 0.01). The value of the share capital remains unchanged at 17’500’000 euro. On June 19, 2018, the Company entered into an issuance agreement with European Select Growth Opportunities The share capital would then be composed of 1’750’000’000 shares of one eurocent (EUR 0.10). The proposed amendment is compliant with Dutch law, since article 2:67 sub 4 of the Dutch Civil Code prescribes that at least one fifth of the authorised share capital must have been issued and that the total share capital value is not modified. In order to be able to effect the amendments in the Company's Articles of Association, the proposal to amend the Articles of Association also includes the grant of authorisation to each member of the Executive Board as well as each employee of the Company Notary to apply for the required ministerial certificate of no-objection and to have executed the notarial deed of amendment to the Articles of Association. 3 The article of association will be updated by the Company Notary and publicly communicated and will be available on the website of the Company (www.esperite.com). 7. Proposal to amend article 22 Financial Year, Annual Accounts of the Company’s Articles of Association - (Voting Item) The Board of Directors of Esperite NV proposes a change in the Company’s fiscal year end to June 30. The change will result in an extended first period from 1st January 2018 to 30th June 2020. This first period, longer than expected is motivated by the shortage of audit ressources in the Netherlands. The background to the proposed change is that the company has found very limited option for the choice of accountants licenced for auditing public companies in the Netherlands. Esperite, since the dismissal of its previous auditor which remitted its licence, has not yet managed to appoint an accountant for the audit of the financial statements for the current financial years 2018 and 2019. The company has undergone several changes in its structure and consolidation perimeter. The company is now confident to be able to report on due time from 30 June 2020. In addition, the company commits to communicate every quarter, starting Q1 2020, detailed market updates including high level financials. With this fiscal year end change, the Company will report one-time, for the period from 1 January 2018 through 30th June 2020 in October 2020. The following fiscal year shall be from 1st July to 30st June. In order to be able to effect the amendments in the Company's Articles of Association, the proposal to amend the Articles of Association also includes the grant of authorisation to each member of the Executive Board as well as each employee of the Company Notary to apply for the required ministerial certificate of no-objection and to have executed the notarial deed of amendment to the Articles of Association. The article of association will be updated by the Company Notary and publicly communicated and will be available on the website of the Company (www.esperite.com). 8. Proposal to appoint two external auditors in relation to the audit of the annual accounts ending 30st June 2020 (Voting Item) In accordance with Article 16(2) of the EU Regulation No 537/2014 regarding the statutory audit of public-interest entities (the Audit Regulation), the Audit Committee recommended two audit firms for the audit engagement to the Board of Directors and expressed its preference
8. Proposal to appoint two external auditors in relation to the audit of the annual accounts ending 30st June 2020 (Voting Item) In accordance with Article 16(2) of the EU Regulation No 537/2014 regarding the statutory audit of public-interest entities (the Audit Regulation), the Audit Committee recommended two audit firms for the audit engagement to the Board of Directors and expressed its preference for Accon. In accordance with Article 16(5) of the Audit Regulation, the Board of Directors has decided to follow the Audit Committee’s preference and proposes to appoint Accon as external auditor in relation to the audit of the annual accounts 2017. As the recommendation by the Audit Committee has been followed by the Board of Directors, the second paragraph of Article 16(5) of the Audit Regulation is not relevant. Please also note that the formal selection procedure as referred to in Article 16(3) of the Audit Regulation does not apply to Esperite, because it qualifies as a small or medium-sized enterprise and a company with reduced market capitalization. Accon avm has announced on 21 March 2019 to shift their focus on providing accounting and advisory to organisations in the public domain and SMEs only. Accon has converted its PIE licence into a regular licence. Despite the commitment of the auditor Accon to complete all PIE engagements, Esperite was left with an unaudited annual report. Esperite has explored all the possible options to deliver its audited annual reports for 2018 and 2019 and 4 therefore, comply to its regulatory obligations. Due to the current shortage of PIE auditors in the Netherlands, Esperite has not been able to appoint an auditor. In accordance with Article 16(2) of the EU Regulation No 537/2014 regarding the statutory audit of public-interest entities (the Audit Regulation), the Audit Committee will recommend two audit firms for the audit engagement to the Board of Directors and will express its preference. In accordance with Article 16(5) of the Audit Regulation, the Board of Directors will express its decision about the Audit Committee’s preference and proposes to appoint two independent audit firms as external auditors in relation to the audit of the accounts ending June 2020. Please also note that the formal selection procedure as referred to in Article 16(3) of the Audit Regulation does not apply to Esperite, because it qualifies as a small or medium-sized enterprise and a company with reduced market capitalization. Once the item accepted, the company will propose two audit firms and appoint them at the next General Meeting. 9. Future Board of Directors configuration. Resignation of Mr. Vincent Borgeot as nonexecutive director of the Company. Mr. Vincent Borgeot formerly non-executive director of the company has resigned for personal reasons. The company will present its intentions and project for a new Board of Directors configuration. 10. Delegation to the Board of Directors of the powers to (a) issue, and grant rights to subscribe for, shares in the capital of the Company up to a maximum aggregate issuance price of EUR 7,000,000; and (b) restrict or exclude the pre-emptive rights in connection with such issue of, or grant of rights to subscribe for shares in the capital of the Company, each for a period of 18 months from the date of the AGM (Voting Item) Proposal to delegate to the Board of Directors of the powers to (a) issue, and grant rights to subscribe for, shares in the capital of the Company up to a maximum aggregate issuance price of EUR 7,000,000; and (b) restrict or exclude the pre-emptive rights in connection with such issue of, or grant of rights to subscribe for shares in the capital of the Company, each for a period of 24 months from the date of the AGM. The Board of Directors considers it desirable to be able to react in a timely manner when certain opportunities that need the issuance of shares or granting of rights to subscribe for shares arise. Therefore the Board of Directors proposes to that this limited authority to issue shares and grant rights to subscribe for shares is delegated to it. 11. Delegation to the Board of Directors, for a period of 24 months from the date of the EGM, of the power to acquire - through purchases on Euronext Amsterdam or otherwise - up to a maximum of 10% of the issued share capital of the Company as at the date of the EGM by acquiring shares for a purchase price not less than the share nominal value price and not higher than the average closing price over the five trading days prior to the date of acquisition at Euronext Amsterdam plus a 10% premium (Voting Item)
6. Proposal to amend article 4 of the Company’s Articles of Association - Change of shares capital nominal value (Voting Item) During the last AGM, on 8 January 2019, the shareholders have approved to increase the value of share capital to 17’500’000,00 euro, composed of 175’000’000 shares of ten eurocent (EUR 0.10). The company’s Board of Directors proposes to reduce the shares nominal value from ten eurocent (EUR 0.10) to one eurocent (EUR 0.01). The value of the share capital remains unchanged at 17’500’000 euro. On June 19, 2018, the Company entered into an issuance agreement with European Select Growth Opportunities The share capital would then be composed of 1’750’000’000 shares of one eurocent (EUR 0.10). Blijkbaar heb ik een fout gemaakt met de titel van dit draadje en had dit moeten zijn:Amar wil bijna 1,7 miljard nieuwe aandelen uitgeven.......!!! ESGOF staat al in de startblokken.....!!!
ESPERITE (ESP) updates on the current business. February 17, 2020 Group News 17 February 2020 Financial and business update Esperite update the market Esperite NV (Esperite, The Company) updates its shareholders on the current configuration and business of the company. The company has taken distance from the operative part of its activities and focus its effort on turning itself in an investment company with a focus on Health Care and High-Tech Service. Esperite-update-on-businesses-17022020.pdf The current subsidiaries of the group, Output Pharma, Genoma with Agaata are now considered as assets held for sale. Therefore, they will not be part any longer of the consolidation perimeter of the group. Esperite was the sole shareholder of CryoSave. First of all, the Company has never been directly managing the daily operations of the Umbilical Stem Cells activities. Furthermore, Esperite and CryoSave are effectively two distinct entities. Finally, Esperite is not a shareholder nor involved any longer with CryoSave or the former cord blood activities. Then, Esperite does not account nor forecast any liability from its former subsidiary Cryo-Save or the current situation. In addition, Esperite is not part of the claims against Cryo-Save. Esperite has already published a Press Release on this topic last week. This major change in the accounting of the company will reveal different metrics, new to Esperite, like growth of capital and long-term earnings. Consequently, Esperite will present quarterly updates including investments, cash flow, cash position, earning, stakes and their valuation. The current cash situation of the company is low but sufficient to maintain the administration at its current level. The shareholders will vote at the next EGM for the reduction of the Shares Nominal Value from 10 eurocents to 1 eurocent. This will allow the company to resume with the investment contracts put on hold. The company is currently talking to a couple of additional investors interested in Esperite’s new strategy. Esperite’s Loan Notes holders have announced they will convert a significant part of their Loan Notes.On 30 June 2019, Esperite announced that it had agreed an extension of the maturity dates for EUR 4,750,000 in unsecured convertible Loan Notes . The Loan Notes bear interest at a rate of 15% per year, payable monthly and are convertible into Esperite shares since 1 January 2020 (or at the earlier occurrence of a limited number of events) until maturity at an initial conversion price of EUR 0.10. The Loan Holders are convinced by the strategy of Esperite and demonstrate their support. Therefore, this decision will reduce the repayment of the due interests and improve the cash position of the company. Esperite has established itself as an investment group which focuses on the health care sectors with strong biotechnology background and activities. Secondary, Financials and IT companies with potential synergies are of interests. As a result, with more than 20 years of experience, Esperite operates now a light and efficient structure dedicated to growth and active development. Esperite follows its strategy to invest primarily in smaller-sized companies valuated at a significant discount to their intrinsic value. Hence, another parameter is essential, it measures the company’s ability to generate free cash flow over the short to mid-term. Future investments would certainly be non-controlling position in durable and good quality businesses. Esperite is now engaging Innovation, Diversification and Sustainability. The Company will inform the shareholders in detail during the EGM scheduled on 26 March 2020.
Esperite’s Loan Notes holders have announced they will convert a significant part of their Loan Notes. On 30 June 2019, Esperite announced that it had agreed an extension of the maturity dates for EUR 4,750,000 in unsecured convertible Loan Notes . The Loan Notes bear interest at a rate of 15% per year, payable monthly and are convertible into Esperite shares since 1 January 2020 (or at the earlier occurrence of a limited number of events) until maturity at an initial conversion price of EUR 0.10. Dit betekent dat Amar z'n lening aan Esperite zeer waarschijnlijk gaat omwisselen in bijna 47,5 miljoen nieuwe aandelen oftewel bijna een verdubbeling van het huidige aandelenkapitaal.
DeZwarteRidder schreef op 26 februari 2020 15:47 :
Esperite’s Loan Notes holders have announced they will convert a significant part of their Loan Notes. On 30 June 2019, Esperite announced that it had agreed an extension of the maturity dates for EUR 4,750,000 in unsecured convertible Loan Notes . The Loan Notes bear interest at a rate of 15% per year, payable monthly and are convertible into Esperite shares since 1 January 2020 (or at the earlier occurrence of a limited number of events) until maturity at an initial conversion price of EUR 0.10. Dit betekent dat Amar z'n lening aan Esperite zeer waarschijnlijk gaat omwisselen in bijna 47,5 miljoen nieuwe aandelen oftewel bijna een verdubbeling van het huidige aandelenkapitaal.
Als ik Amar was dan zou ik wachten met conversie totdat de nominale waarde is afgestempeld tot 1 cent, want dat scheelt bijna een half miljard aandelen.
succes ridder met je gevecht met Amar.
Esperite NV (Esperite, The Company) updates its shareholders on the current configuration and business of the company. The company has taken distance from the operative part of its activities and focus its effort on turning itself in an investment company with a focus on Health Care and High-Tech Service. ***PDF Downloads Esperite-update-on-businesses-17022020.pdf The current subsidiaries of the group, Output Pharma, Genoma with Agaata are now considered as assets held for sale. Therefore, they will not be part any longer of the consolidation perimeter of the group. Esperite was the sole shareholder of CryoSave. First of all, the Company has never been directly managing the daily operations of the Umbilical Stem Cells activities. Furthermore, Esperite and CryoSave are effectively two distinct entities. Finally, Esperite is not a shareholder nor involved any longer with CryoSave or the former cord blood activities. Then, Esperite does not account nor forecast any liability from its former subsidiary Cryo-Save or the current situation. In addition, Esperite is not part of the claims against Cryo-Save. Esperite has already published a Press Release on this topic last week. This major change in the accounting of the company will reveal different metrics, new to Esperite, like growth of capital and long-term earnings. Consequently, Esperite will present quarterly updates including investments, cash flow, cash position, earning, stakes and their valuation. The current cash situation of the company is low but sufficient to maintain the administration at its current level. The shareholders will vote at the next EGM for the reduction of the Shares Nominal Value from 10 eurocents to 1 eurocent. This will allow the company to resume with the investment contracts put on hold. The company is currently talking to a couple of additional investors interested in Esperite’s new strategy. Esperite’s Loan Notes holders have announced they will convert a significant part of their Loan Notes. On 30 June 2019, Esperite announced that it had agreed an extension of the maturity dates for EUR 4,750,000 in unsecured convertible Loan Notes . The Loan Notes bear interest at a rate of 15% per year, payable monthly and are convertible into Esperite shares since 1 January 2020 (or at the earlier occurrence of a limited number of events) until maturity at an initial conversion price of EUR 0.10. The Loan Holders are convinced by the strategy of Esperite and demonstrate their support. Therefore, this decision will reduce the repayment of the due interests and improve the cash position of the company. Esperite has established itself as an investment group which focuses on the health care sectors with strong biotechnology background and activities. Secondary, Financials and IT companies with potential synergies are of interests. As a result, with more than 20 years of experience, Esperite operates now a light and efficient structure dedicated to growth and active development. Esperite follows its strategy to invest primarily in smaller-sized companies valuated at a significant discount to their intrinsic value. Hence, another parameter is essential, it measures the company’s ability to generate free cash flow over the short to mid-term. Future investments would certainly be non-controlling position in durable and good quality businesses. Esperite is now engaging Innovation, Diversification and Sustainability. The Company will inform the shareholders in detail during the EGM scheduled on 26 March 2020.
Change of Business Address location Esperite NV is registered in Piet Heinstraat 11, 7204 JN Zutphen, Netherlands with a business address in Herengracht 282, 1016 BX Amsterdam Netherlands. The Board of Directors has decided to move the Business Address to France, Immeuble le Patio, 35-37 Rue Louis Guérin, 69100 Villeurbanne France. Since 7 January 2020: The Company’s visiting and business address is now established in France; The actual headquarter operations, board meetings and General meetings are at the address of the new headquarters The company will conduct the necessary process to recruit and appoint a minimum of two French board members. The daily operations and administrative tasks are conducted by local team of employees which carry out their work in the headquarter address; The Company will conduct the necessary actions in order to be regulated by the French regulator; 5. Annual report 2018 – including Corporate Governance Consideration of the annual report by the Board of Directors for the 2018 financial year. In accordance with the principles of the Dutch Corporate Governance Code, the Company's approach to the implementation of the Dutch Corporate Governance Code as set out in the annual report is tabled for discussion at the AGM. The company has not been able to finalize its annual report for the year 2018 on due course. The company proposes to present an unaudited annual for 2018 to its shareholders. The Company is taking all the possible measure to remedy. The company will present to the shareholders a summarized annual report 2018, a market update for 2019 as well as half year figure for 2019. 6. Proposal to amend article 4 of the Company’s Articles of Association - Change of shares capital nominal value (Voting Item) During the last AGM, on 8 January 2019, the shareholders have approved to increase the value of share capital to 17’500’000,00 euro, composed of 175’000’000 shares of ten eurocent (EUR 0.10). The company’s Board of Directors proposes to reduce the shares nominal value from ten eurocent (EUR 0.10) to one eurocent (EUR 0.01). The value of the share capital remains unchanged at 17’500’000 euro. On June 19, 2018, the Company entered into an issuance agreement with European Select Growth Opportunities The share capital would then be composed of 1’750’000’000 shares of one eurocent (EUR 0.01). The proposed amendment is compliant with Dutch law, since article 2:67 sub 4 of the Dutch Civil Code prescribes that at least one fifth of the authorised share capital must have been issued and that the total share capital value is not modified. In order to be able to effect the amendments in the Company's Articles of Association, the proposal to amend the Articles of Association also includes the grant of authorisation to each member of the Executive Board as well as each employee of the Company Notary to apply for the required ministerial certificate of no-objection and to have executed the notarial deed of amendment to the Articles of Association. The article of association will be updated by the Company Notary and publicly communicated and will be available on the website of the Company (www.esperite.com). 3 7. Proposal to amend article 22 Financial Year, Annual Accounts of the Company’s Articles of Association - (Voting Item) The Board of Directors of Esperite NV proposes a change in the Company’s fiscal year end to June 30. The change will result in an extended first period from 1st January 2018 to 30th June 2020. This first period, longer than expected is motivated by the shortage of audit resources in the Netherlands. The background to the proposed change is that the company has found very limited option for the choice of accountants licenced for auditing public companies in the Netherlands. Esperite, since the dismissal of its previous auditor which remitted its licence, has not yet managed to appoint an accountant for the audit of the financial statements for the current financial years 2018 and 2019. The company has undergone several changes in its structure and consolidation perimeter. The company is now confident to be able to report on due time from 30 June 2020. In addition, the company commits to communicate every quarter, starting Q1 2020, detailed market updates including high level financials. With this fiscal year end change, the Company will report one-time, for the period from 1 January 2018 through 30th June 2020 in October 2020. The following fiscal year shall be from 1st July to 30st June. In order to be able to effect the amendments in the Company's Articles of Association, the proposal to amend the Articles of Association also includes the grant of authorisation to each member of the Executive Board as well as each employee of the Company Notary to apply for the required ministerial certificate of no-objection and to have executed the notarial deed of amendment to the Articles of Association. The article of association will be updated by the Company Notary and publicly communicated and will be available on the website of the Company (www.esperite.com). 8. Proposal to appoint two external auditors in relation to the audit of the annual accounts ending 30st June 2020 (Voting Item) In accordance with Article 16(2) of the EU Regulation No 537/2014 regarding the statutory audit of public-interest entities (the Audit Regulation), the Audit Committee recommended two audit firms for the audit engagement to the Board of Directors and expressed its preference for Accon. In accordance with Article 16(5) of the Audit Regulation, the Board of Directors has decided to follow the Audit Committee’s preference and proposes to appoint Accon as external auditor in relation to the audit of the annual accounts 2018. As the recommendation by the Audit Committee has been followed by the Board of Directors, the second paragraph of Article 16(5) of the Audit Regulation is not relevant. Please also note that the formal selection procedure as referred to in Article 16(3) of the Audit Regulation does not apply to Esperite, because it qualifies as a small or medium-sized enterprise and a company with reduced market capitalization. Accon avm has announced on 21 March 2019 to shift their focus on providing accounting and advisory to organisations in the public domain and SMEs only. Accon has converted its PIE licence into a regular licence. Despite the commitment of the auditor Accon to complete all PIE engagements, Esperite was left with an unaudited annual report. Esperite has explored all the possible options to deliver its audited annual reports for 2018 and 2019 and therefore, comply to its regulatory obligations. Due to the current shortage of PIE auditors in the Netherlands, Esperite has not been able to appoint an auditor. 4 In accordance with Article 16(2) of the EU Regulation No 537/2014 regarding the statutory audit of public-interest entities (the Audit Regulation), the Audit Committee will recommend two audit firms for the audit engagement to the Board of Directors and will express its preference. In accordance with Article 16
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
860,01
-0,62%
EUR/USD
1,0655
+0,11%
FTSE 100
7.895,85
+0,24%
Germany40^
17.714,20
-0,13%
Gold spot
2.392,50
0,00%
NY-Nasdaq Composite
15.282,01
-2,05%
Stijgers
Dalers